Ribo Cure's siRNA Drug RBD2080 for Autoimmune Diseases Receives TGA Approval to Commence Phase I Clinical Trial in Australia

Ribo Life Science announced today that its self-developed siRNA drug RBD2080 for the treatment of autoimmune diseases has been approved by the Therapeutic Goods Administration (TGA) of Australia and will soon commence Phase I clinical trials in Australia.

This clinical trial is a Phase I, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD2080 in healthy subjects following single and multiple ascending doses.

RBD2080 is a product developed by the company based on RIBO-GalSTAR.^TMRBD2080, the sixth innovative small nucleic acid drug developed on the liver-targeting technology platform, precisely targets specific genes associated with autoimmune diseases, effectively regulating gene expression and fundamentally intervening in disease progression. Compared with traditional treatment methods, RBD2080 offers advantages such as precise targeting and long-lasting efficacy, providing the potential for a superior treatment option for patients.

Ribo Life Science has been committed to providing innovative therapeutic solutions for patients worldwide and continuously increasing R&D investment in the field of autoimmune disease treatment. The approval of RBD2080 for clinical trials reflects the company's differentiated product portfolio strategy and marks another significant milestone in Ribo Life Science’s path of innovation and development. The company will soon initiate the relevant clinical trials and looks forward to the drug’s excellent clinical performance.